Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 243

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Targeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review

Targeted Alpha Therapy Working Group, Parker, Christopher, Lewington, Valerie, Shore, Neal, Kratochwil, Clemens, Levy, Moshe, Lindén, Ola, Noordzij, Walter, Park, Jae, Saad, Fred · 2018 · JAMA Oncology

Abstract

Importance: Targeted alpha therapy attempts to deliver systemic radiation selectively to cancer cells while minimizing systemic toxic effects and may lead to additional treatment options for many cancer types. Observations: Theoretically, the high-energy emission of short-range alpha particles causes complex double-stranded DNA breaks, eliciting cell death. No known resistance mechanism to alpha particles has been reported or scientifically established. The short-range emission of alpha particle radiation confines its cytotoxic effect to cancerous lesions and the surrounding tumor microenvironment while limiting toxic effects to noncancerous tissues. The high level of radiobiological effectiveness of alpha particles, in comparison with beta emissions, requires fewer particle tracks to induce cell death. Clinically effective alpha particle-emitting isotopes for cancer therapy should have a short half-life, which will limit long-term radiation exposure and allow for the production, preparation, and administration of these isotopes for clinical use and application. Radium 223 dichloride is the first-in-class, commercially available targeted alpha therapy approved for the treatment of patients with metastatic castration-resistant prostate cancer with bone metastases. Given the established overall survival benefit conferred by radium 223 for patients with metastatic castration-resistant prostate cancer, several other targeted alpha therapies are being investigated in clinical trials across many tumor types. Conclusions and Relevance: Targeted alpha therapy represents an emerging treatment approach and provides for the possibility to bypass mechanisms of acquired resistance in selected tumors. In addition, developing novel radionuclide conjugation strategies may overcome targeting limitations. So far, the clinical success of radium 223 has demonstrated the proof of concept for targeted alpha therapy, and future studies may lead to additional treatment options for many cancer types.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamaoncol.2018.4044

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 243

Metadata

Authors
Targeted Alpha Therapy Working Group, Parker, C., Lewington, V., Shore, N., Kratochwil, C., Levy, M., Lindén, O., Noordzij, W., Park, J., & Saad, F.
Venue
JAMA Oncology
Published
2018-12-01
Volume
4
Issue
12
Pages
1765
ISSN
2374-2437 (ISSN-L)
OpenAlex
W2891647981
Cited by
243
References
5
FWCI
11.18
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review. https://app.cochat.ai/papers/10.1001/jamaoncol.2018.4044
The paper
Targeted Alpha Therapy Working Group, Parker, C., Lewington, V., Shore, N., Kratochwil, C., Levy, M., Lindén, O., Noordzij, W., Park, J., & Saad, F. (2018). Targeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2018.4044

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.